Decreased IL-10(+) regulatory B cells (Bregs) in lupus nephritis patients
- PMID: 26948375
- DOI: 10.3109/03009742.2015.1126346
Decreased IL-10(+) regulatory B cells (Bregs) in lupus nephritis patients
Abstract
Objectives: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by B cell-dependent autoantibody production. Recently, a new B-cell subset was discovered that has a regulatory capacity. The aim of this study was to analyse regulatory B cells (Bregs) in SLE patients.
Method: Peripheral mononuclear blood cells (PBMCs) of 34 SLE patients fulfilling the American College of Rheumatology (ACR) criteria for SLE and 21 healthy controls (HC) were included. PBMCs were stained for CD19, CD24, and CD38 and analysed by flow cytometry. In vitro stimulated PBMCs with CpG and restimulated with phorbol 12-myristate 13-acetate (PMA) and ionomycin were investigated for IL-10(+) Bregs .
Results: The percentages of circulating CD19(+)CD24(hi)CD38(hi) cells in HC were not different those in from SLE patients. The percentages of IL-10(+) Bregs were significantly decreased in SLE patients, in particular those with lupus nephritis (LN), compared to HC. The proportion was independent of disease activity.
Conclusions: This is the first study to demonstrate a decrease in IL-10-producing B cells in LN patients compared to HC, reflecting an impaired regulatory function.
Similar articles
-
Regulatory B cells (CD19(+)CD38(hi)CD24(hi)) in alloimmunized and non-alloimmunized children with β-thalassemia major.Blood Cells Mol Dis. 2016 Mar;57:91-6. doi: 10.1016/j.bcmd.2016.01.005. Epub 2016 Jan 20. Blood Cells Mol Dis. 2016. PMID: 26852663
-
Impaired function of CD19(+) CD24(hi) CD38(hi) regulatory B cells in patients with pemphigus.Br J Dermatol. 2015 Jan;172(1):101-10. doi: 10.1111/bjd.13192. Epub 2014 Nov 20. Br J Dermatol. 2015. PMID: 24935080
-
Reduced CD5(+) CD24(hi) CD38(hi) and interleukin-10(+) regulatory B cells in active anti-neutrophil cytoplasmic autoantibody-associated vasculitis permit increased circulating autoantibodies.Clin Exp Immunol. 2015 May;180(2):178-88. doi: 10.1111/cei.12483. Clin Exp Immunol. 2015. PMID: 25376552 Free PMC article. Clinical Trial.
-
Regulatory B and T cell responses in patients with autoimmune thyroid disease and healthy controls.Dan Med J. 2016 Feb;63(2):B5177. Dan Med J. 2016. PMID: 26836805 Review.
-
The role of B regulatory (B10) cells in inflammatory disorders and their potential as therapeutic targets.Int Immunopharmacol. 2020 Jan;78:106111. doi: 10.1016/j.intimp.2019.106111. Epub 2019 Dec 24. Int Immunopharmacol. 2020. PMID: 31881524 Review.
Cited by
-
Single-cell RNA sequencing analysis reveals the heterogeneity of IL-10 producing regulatory B cells in lupus-prone mice.Front Immunol. 2023 Dec 14;14:1282770. doi: 10.3389/fimmu.2023.1282770. eCollection 2023. Front Immunol. 2023. PMID: 38155972 Free PMC article.
-
B Cell Tolerance and Targeted Therapies in SLE.J Clin Med. 2023 Sep 28;12(19):6268. doi: 10.3390/jcm12196268. J Clin Med. 2023. PMID: 37834911 Free PMC article. Review.
-
Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus.Front Immunol. 2023 Sep 12;14:1230264. doi: 10.3389/fimmu.2023.1230264. eCollection 2023. Front Immunol. 2023. PMID: 37771588 Free PMC article. Review.
-
Impaired regulatory function of granzyme B-producing B cells against T cell inflammatory responses in lupus mice.Lupus Sci Med. 2023 Jul;10(2):e000974. doi: 10.1136/lupus-2023-000974. Lupus Sci Med. 2023. PMID: 37500293 Free PMC article.
-
The emerging role of regulatory cell-based therapy in autoimmune disease.Front Immunol. 2022 Dec 14;13:1075813. doi: 10.3389/fimmu.2022.1075813. eCollection 2022. Front Immunol. 2022. PMID: 36591309 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
